Melhores Metaplasia gástrica médicos em Israel - TOP-7 médicos

A Dra. Pelles Sharon é uma oncologista altamente respeitada, especializada em cirurgia de cancro gástrico no Sourasky Medical Center (Ichilov).

• Realizar investigação clínica inovadora sobre a atitude dos pacientes oncológicos perante ensaios clínicos
• Executar procedimentos avançados, tais como HIPEC e a cirurgia de Whipple
• Ser qualificada em tratamentos oncológicos cirúrgicos e não cirúrgicos

Especialista em cirurgia abdominal aberta e minimamente invasiva, incluindo o complexo procedimento de Whipple. Ele chefia o Departamento de Cirurgia Colorretal do Sourasky Medical Center (Ichilov).

• Mais de 20 anos de experiência cirúrgica
• Especialista em técnicas avançadas minimamente invasivas
• Chefe de departamento, liderando uma equipa cirúrgica especializada

Como Chefe do Centro de Câncer Gastrointestinal, o Dr. Hubert lidera uma unidade especializada em cancros digestivos complexos.

• 33 anos de experiência clínica em oncologia e radioterapia
• Dupla certificação de especialista em oncologia e radioterapia
• Médico sénior no Hospital Universitário Hadassah
• Membro ativo do Comité de Israel para o Cancro Gastrointestinal
• Formação inclui licenciatura em medicina e em psicologia

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.